氯氮平与奈玛特韦/利托那韦联用未见明显相互作用:一例轻度COVID-19感染病例报告及其他氯氮平相关CYP3A4相互作用综述
一例75岁女性精神分裂症患者,长期服用氯氮平200 mg每晚,在发生轻度COVID-19感染后启用奈玛特韦/利托那韦。两天后因不明原因跌倒至急诊,怀疑氯氮平中毒但无其他症状。氯氮平血药浓度监测未显示与基线相比存在相互作用。病例提示,尽管理论担忧CYP3A4抑制,但本病例不明确支持奈玛特韦/利托那韦与氯氮平存在相互作用。
要点
- 氯氮平主要经CYP1A2代谢,CYP3A4也参与代谢,奈玛特韦/利托那韦为CYP3A4抑制剂。
- 本病例中,联用奈玛特韦/利托那韦后氯氮平血药浓度与基线相比无变化。
- 文献综述提示CYP3A4抑制剂或基因多态性对氯氮平水平影响似乎很小,但仍需临床监测。
核心结论
- 本病例未观察到奈玛特韦/利托那韦与氯氮平之间存在明显相互作用。
- 尽管存在CYP3A4抑制的理论担忧,但来自本病例的信息不明确支持联用奈玛特韦/利托那韦时发生相互作用。
- 文献综述提示CYP3A4抑制剂或基因多态性对氯氮平水平影响似乎很小,但仍需临床监测。
研究设计与样本
- 病例报告,涉及一例75岁女性精神分裂症患者,长期服用氯氮平200 mg每晚。
- 患者发生轻度COVID-19感染后启用奈玛特韦/利托那韦。
- 报告包含对氯氮平相关CYP3A4药物和基因相互作用的文献综述。
主要发现
- 患者启用奈玛特韦/利托那韦两天后因不明原因跌倒至急诊,怀疑氯氮平中毒但无其他氯氮平水平升高的症状或体征。
- 停用奈玛特韦/利托那韦,氯氮平暂停1天等待血药浓度结果,结果与基线氯氮平水平相比未显示相互作用。
- 未出现精神科相关问题。
临床怎么用
- 在轻度COVID-19感染期间,联用奈玛特韦/利托那韦时,可考虑监测氯氮平血药浓度以评估相互作用。
- 需权衡暂停氯氮平的风险,尽管本病例未出现精神科问题。
- 临床监测是必要的,尤其对于CYP3A4抑制剂与氯氮平联用的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clozapine is primarily metabolized by cytochrome P450 (CYP) 1A2 and to a lesser extent by CYP2C19, CYP2D6, and CYP3A4. The global pandemic of coronavirus disease 2019 (COVID-19) and use of nirmatrelvir/ritonavir brought forth new challenges for those caring for patients prescribed clozapine. Prescribing information describes a consideration for a clozapine dose reduction while monitoring for adverse reactions when clozapine is used with nirmatrelvir/ritonavir. Other drug information resources consider the combination a contraindication. A case is reported in which therapeutic drug monitoring demonstrated a lack of interaction between clozapine and nirmatrelvir/ritonavir. The complexities of infection-associated clozapine toxicity are discussed and a review is provided of CYP3A4 drug and gene interactions with clozapine. SUMMARY: A 75-year-old woman with schizophrenia, prescribed clozapine 200 mg by mouth at bedtime, was initiated on nirmatrelvir/ritonavir after developing a mild COVID-19 infection. Two days later, the patient was brought to the emergency department after an unwitnessed fall. Clozapine toxicity was included in the differential diagnosis, although no other signs or symptoms of elevated clozapine levels were present. Nirmatrelvir/ritonavir was discontinued. Clozapine was withheld for 1 day while a clozapine level was pending, but this measurement revealed no interaction when compared to a baseline level of clozapine. CONCLUSION: Although there are hypothetical concerns when initiating a CYP3A4 inhibitor with concomitant clozapine, the information derived from this case does not clearly support an interaction with the addition of nirmatrelvir/ritonavir during mild COVID-19 infection. It is important to understand the risks of withholding clozapine, although fortunately no psychiatric concerns developed. In reviewing the literature, CYP3A4 inhibitors or genetic polymorphisms seem to have a minimal impact on clozapine levels, although clinical monitoring is warranted.
引用
- Leung JG, Schmitt CJ, Kuhn AK, et al. Clozapine and nirmatrelvir/ritonavir coadministration without apparent interaction in a patient with mild COVID-19 infection: A case with review of other clozapine-related CYP3A4 interactions. Am J Health Syst Pharm. 2025. PMID: 40576539. doi:10.1093/ajhp/zxaf156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。